{"product_id":"nus-vrio-analysis","title":"Nu Skin Enterprises, Inc. (NUS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Nu Skin Enterprises, Inc. (NUS) truly built to last? This VRIO analysis cuts straight to the core, dissecting whether its current resources offer a sustainable competitive edge through Value, Rarity, Inimitability, and Organization. Discover the definitive verdict on what truly separates Nu Skin Enterprises, Inc. (NUS) from the competition and where its next strategic move must lie - read the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Proprietary Scientific Database \u0026amp; R\u0026amp;D Infrastructure\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the engine room of Nu Skin Enterprises, Inc. (NUS)  -  their deep, proprietary science. This isn't just marketing fluff; it’s a tangible asset that underpins their premium pricing and product differentiation, especially as they roll out the Prysm iO platform in late 2025.\u003c\/p\u003e\n\n\u003ch\u003eValue: Foundation for Differentiated Products\u003c\/h\u003e\n\u003cp\u003eThis scientific database is definitely valuable because it directly supports high-margin, differentiated products. Think about the Prysm iO intelligent wellness device, which had its limited sales leader preview in Q4 2025. This device measures skin carotenoid levels to give an immediate antioxidant score, a capability that comes straight from their massive data repository. For the full 2025 fiscal year, management is projecting revenue between \u003cstrong\u003e$1.48 billion and $1.51 billion\u003c\/strong\u003e, and this science is what justifies the premium positioning needed to maintain their strong gross margin, which hit \u003cstrong\u003e70.5%\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the data asset:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDatabase leverages data from over \u003cstrong\u003e20 million scans\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe science is backed by nearly \u003cstrong\u003e40 years\u003c\/strong\u003e of research.\u003c\/li\u003e\n\u003cli\u003eIt powers personalized recommendations via the Prysm iO’s AI app.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the ongoing cost to maintain and expand this data, but the revenue potential from new, science-backed devices makes the investment worthwhile.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Longitudinal and Scale Advantage\u003c\/h\u003e\n\u003cp\u003eThe sheer scale and, critically, the \u003cstrong\u003elongitudinal nature\u003c\/strong\u003e of this antioxidant database are what make it rare in the direct selling space. Most competitors might have product-specific clinical trials, but few have spent four decades collecting multi-country, longitudinal data points. This depth of historical data is not something you can buy off the shelf, and it’s a key differentiator against newer entrants in the wellness tech space.\u003c\/p\u003e\n\n\u003ch\u003eImitability: High Barrier to Entry\u003c\/h\u003e\n\u003cp\u003eReplicating this asset would be incredibly tough. It’s not just about the technology; it’s about the time and capital sunk into collecting the data. To match \u003cstrong\u003e40 years\u003c\/strong\u003e of R\u0026amp;D and the massive, multi-country scan database would take a competitor decades and significant, patient capital - something most firms are unwilling or unable to commit to in the near term. If onboarding a new technology takes 14+ days, churn risk rises, but replicating 40 years of science takes 40 years.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Active Integration for Advantage\u003c\/h\u003e\n\u003cp\u003eNu Skin Enterprises, Inc. is showing high organization by actively weaving this science into their current and future product roadmap. The limited preview of the Prysm iO device in Q4 2025 is concrete proof they are structured to commercialize this R\u0026amp;D. They are also preparing for a formal launch in India in the second half of 2026, which will require leveraging this global scientific base for localized product relevance.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick scoring of this resource:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnables premium pricing and differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e40 years of longitudinal data is unique\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eRequires decades of investment to replicate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eActively launching Prysm iO based on data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained Potential\u003c\/h\u003e\n\u003cp\u003eBecause the database is valuable, rare, and difficult to imitate, and the company is organized to use it, this resource points toward a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. The challenge for NUS will be to keep innovating faster than competitors can close the gap on newer technologies, like the AI integration they are pushing.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDatabase size: \u003cstrong\u003e20 million+ scans\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D history: Over \u003cstrong\u003e40 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNear-term action: Ensure smooth Q1 2026 consumer launch for Prysm iO.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft the 13-week cash view by Friday, factoring in the capital required for the India market build-out.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Global Beauty Device System Market Leadership\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eRecognized as the \u003cstrong\u003eWorld's No. 1 Company for Beauty and Wellness Device Systems\u003c\/strong\u003e by Euromonitor International Ltd. for the second consecutive year as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e. This leadership is supported by an innovation pipeline utilizing AI capabilities with a database of \u003cstrong\u003e20 million scans over 20 years\u003c\/strong\u003e. The ageLOC beauty products, which include the device systems, accounted for \u003cstrong\u003e20%\u003c\/strong\u003e of total revenue in \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023\u003c\/th\u003e\n\u003cth\u003e2022\u003c\/th\u003e\n\u003cth\u003e2021\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice \u0026amp; Consumables Sales (Millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$342 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$440 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$658 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eageLOC Beauty Products as % of Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eAchieving the \u003cstrong\u003eNo. 1\u003c\/strong\u003e global ranking for \u003cstrong\u003etwo consecutive years\u003c\/strong\u003e by Euromonitor International Ltd. indicates a rare market position within the direct selling channel. The company operates across nearly \u003cstrong\u003e50 global markets\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe current title is maintained through a broad portfolio including the ageLOC LumiSpa iO and the upcoming launch of the Prysm iO intelligent wellness device. The company is backed by nearly \u003cstrong\u003e40 years of scientific research\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eManagement highlights this device leadership as a key pillar in the strategy to return to growth. The organization maintains financial commitments, evidenced by a declared quarterly cash dividend of \u003cstrong\u003e$0.06 per share\u003c\/strong\u003e as of November 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGlobal Markets: Nearly \u003cstrong\u003e50\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal 2023 Revenue: Approximately \u003cstrong\u003e$1.97B\u003c\/strong\u003e to \u003cstrong\u003e$2.0 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Rhyz Manufacturing \u0026amp; Technology Ecosystem\n\u003c\/h2\u003e\n\u003cp\u003eRhyz Manufacturing \u0026amp; Technology Ecosystem Performance Metrics\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eRhyz Manufacturing Segment Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eTotal Company Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$386.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003eRhyz Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003eRhyz Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003eRhyz Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$62.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003ctd\u003eRhyz Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2023\u003c\/td\u003e\n\u003ctd\u003eRhyz Revenue as % of Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13 percent\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eProvides internal control over supply, quality, and innovation, shown by the segment growing \u003cstrong\u003e17%\u003c\/strong\u003e year-over-year in Q2 2025 revenue.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Having a dedicated, growing manufacturing arm that supports the core business is uncommon for many peers.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. Competitors can acquire or build similar capabilities, but Nu Skin's integration is established.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. The segment's strong growth contrasts with the core business's struggles, showing effective internal alignment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eRhyz Manufacturing Segment Revenue Growth (YoY) in Q2 2025: \u003cstrong\u003e17%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRhyz Revenue in Q2 2024: \u003cstrong\u003e$67.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRhyz Revenue in Q1 2024: \u003cstrong\u003e$62.5 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eStrategic transaction for Mavely (part of Rhyz) in 2024: \u003cstrong\u003e$250 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Strengthened Balance Sheet \u0026amp; Liquidity\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrengthened Balance Sheet \u0026amp; Liquidity\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eValue: Provides financial flexibility to fund strategic pivots (like India expansion) and weather market volatility, evidenced by a positive net cash position achieved ahead of schedule. For Q3 2025, Cash and cash equivalents were reported at \u003cstrong\u003e$251.8 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$186.9 million\u003c\/strong\u003e at year-end 2024.\u003c\/p\u003e\n\n\u003cp\u003eRarity: Moderate. Many peers in the sector carry higher leverage; achieving a positive net cash position is a significant recent feat. The company closed Q3 2025 with an expanded positive net cash position after reducing total debt by \u003cstrong\u003e$20 million\u003c\/strong\u003e in the quarter.\u003c\/p\u003e\n\n\u003cp\u003eImitability: High. While competitors can cut costs, achieving this specific level of debt reduction is unique to their recent actions. Long-term debt fell to \u003cstrong\u003e$209.0 million\u003c\/strong\u003e by Q3 2025 from \u003cstrong\u003e$363.6 million\u003c\/strong\u003e at year-end 2024, aided by \u003cstrong\u003e$220.0 million\u003c\/strong\u003e of debt payments year-to-date.\u003c\/p\u003e\n\n\u003cp\u003eOrganization: High. The CFO explicitly links this strength to their ability to fund growth initiatives. The board declared a quarterly cash dividend of \u003cstrong\u003e$0.06\u003c\/strong\u003e per share, payable on December 10, 2025, to shareholders of record on November 28, 2025.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Advantage: Sustained.\u003c\/p\u003e\n\n\u003cp\u003eThe following table details key balance sheet metrics supporting the strengthened liquidity position:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (USD Millions unless noted)\u003c\/th\u003e\n\u003cth\u003eQ3 2025 (As of Sep 30, 2025)\u003c\/th\u003e\n\u003cth\u003eYear-End 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$251.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$186.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-Term Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$209.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$363.6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Payments YTD 2025 (9 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$220.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerm-Loan Paydown YTD 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$115.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClass A Shares Outstanding (As of Nov 1, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48,750,076\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe operational discipline contributed to margin expansion, further supporting the balance sheet strength:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Gross Margin: \u003cstrong\u003e70.5%\u003c\/strong\u003e compared to 70.1% in the prior year.\u003c\/li\u003e\n\u003cli\u003eNu Skin core business Gross Margin: \u003cstrong\u003e77.7%\u003c\/strong\u003e, up 120 basis points from the prior year.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Operating Margin: \u003cstrong\u003e5.9%\u003c\/strong\u003e, up from 4.2% year-over-year.\u003c\/li\u003e\n\u003cli\u003eSelling Expenses as a percentage of revenues (Q3 2025): \u003cstrong\u003e35.8%\u003c\/strong\u003e company-wide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Direct Selling Model with Enhanced Compensation\n\u003c\/h2\u003e\n\u003cp\u003eValue: The core distribution engine, which, despite affiliate declines (e.g., \u003cstrong\u003e23%\u003c\/strong\u003e drop in Sales Leaders in Q2 2025), is being actively reinforced with an enhanced sales performance compensation plan. The organization is focused on stabilizing the field force through new programs, evidenced by progress in building sales leader engagement for late 2025 and 2026 initiatives, including the mid-Q4 limited preview of the Prysm iO device. Latin America demonstrated a \u003cstrong\u003e107%\u003c\/strong\u003e year-over-year revenue growth, while the Rhyz Manufacturing segment grew revenue by \u003cstrong\u003e17%\u003c\/strong\u003e year-over-year in Q2 2025.\u003c\/p\u003e\n\u003cp\u003eRarity: Low. The direct selling model itself is common, but the specific structure and its current state of flux are not unique.\u003c\/p\u003e\n\u003cp\u003eImitability: Low. Competitors can copy compensation plans, but replicating the existing, albeit challenged, global field force is difficult.\u003c\/p\u003e\n\u003cp\u003eOrganization: Moderate. The organization is clearly focused on stabilizing the field force through new programs.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary.\u003c\/p\u003e\n\u003cp\u003eKey Statistical and Financial Metrics (Q2 2025):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$386.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(12.1)%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Customers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e771,407\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(14)%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePaid Affiliates\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e130,799\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(16)%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales Leaders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29,593\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e(23)%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImprovement from (28.6)%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.43\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImprovement from $(2.38)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNu Skin Business Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from 76.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDetails on the Enhanced Sales Performance Plan Rollout and Structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe new Sales Performance Plan is being rolled out globally beginning in 2024 through \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe enhanced Selling Bonus ranges from \u003cstrong\u003e4% to 21%\u003c\/strong\u003e of the Product's Net Sales Price, dependent on total Direct Customer Sales Volume for the month.\u003c\/li\u003e\n\u003cli\u003eThe Selling Bonus is paid daily at an immediate \u003cstrong\u003e4%\u003c\/strong\u003e, with the percentage increasing retroactively for the entire month's sales if higher targets are met.\u003c\/li\u003e\n\u003cli\u003eThe Sharing Bonus has been replaced with the enhanced Selling Bonus.\u003c\/li\u003e\n\u003cli\u003eThe plan adds a new Referring Bonus, where compensation can range from \u003cstrong\u003e4% to 24%\u003c\/strong\u003e on the cash value of purchases made by Direct Customers of Brand Affiliates.\u003c\/li\u003e\n\u003cli\u003eIn 2024, the average monthly sales compensation paid to U.S. Brand Affiliates who earned a sales compensation payment was \u003cstrong\u003e$826.37\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn 2024, the Company paid approximately \u003cstrong\u003e$122,224,000\u003c\/strong\u003e in sales compensation to Brand Affiliates residing in the United States.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Intelligent Wellness Platform Innovation (Prysm iO)\n\u003c\/h2\u003e\n\u003cp\u003eThe Prysm iO platform represents a strategic pivot toward connected, personalized wellness solutions.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe platform aims to convert device users into paying subscribers, where a subscribed customer is projected to be worth seven times more over their lifetime compared to non-subscribed customers. This is intended to create a high-value recurring revenue stream. The intelligent wellness wearables market was valued at $84 billion in 2024.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThe specific integration of skin\/health scanning technology with the established direct selling supplement\/nutrition model is novel. Management has stated plans to place more than 10,000 Prysm iO units in Q4 (2025), with tens of thousands of units placed per quarter throughout 2026.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe technology is new, and the required data infrastructure provides a significant lead time advantage, built upon the company's reported 40 years of R\u0026amp;D and a treasure trove of millions of scans. The technology leverages AI and machine learning for personalized insights.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eManagement is making this a key priority for rollout. A limited sales leader preview is planned for late Q4 (2025), followed by broader sales leader availability and a full consumer launch in 2026. The company reported Q3 2025 revenue of $364.2 million and projected full-year 2025 revenue between $1.48 billion and $1.51 billion.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrysm iO Unit Placement Goal (Q4)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMore than 10,000\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eQ4 2025 (Limited Preview)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Customer Lifetime Value Multiplier\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eSeven times\u003c\/strong\u003e more\u003c\/td\u003e\n\u003ctd\u003eSubscribed Customer vs. Non-Subscribed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntelligent Wellness Wearables Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$84 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$364.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.34\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (High end of guidance)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore Nu Skin Business Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Reserves\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$252 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe platform's success is tied to the following operational milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLimited sales leader preview in late Q4 (2025).\u003c\/li\u003e\n\u003cli\u003eFull consumer launch anticipated in 2026.\u003c\/li\u003e\n\u003cli\u003eLeveraging over 20 years of scientific studies and R\u0026amp;D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Developing Market Expansion Strategy\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eDeveloping Market Expansion Strategy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Taps into massive, underpenetrated markets to offset weakness in mature regions, exemplified by \u003cstrong\u003e107%\u003c\/strong\u003e year-over-year revenue growth in Latin America in Q2 2025 and the planned India launch. The overall Q2 2025 revenue was \u003cstrong\u003e$386.1 million\u003c\/strong\u003e, with an operating margin of \u003cstrong\u003e8%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies target developing markets, but Nu Skin's specific, localized approach is tailored. The India entry is noted as the \u003cstrong\u003eFIRST-EVER\u003c\/strong\u003e pre-marketing event in Nu Skin's \u003cstrong\u003e40-YEAR\u003c\/strong\u003e history.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can enter these markets, but Nu Skin has a head start with pre-opening activities planned for \u003cstrong\u003eQ4 2025\u003c\/strong\u003e, with a formal launch anticipated for mid-\u003cstrong\u003e2026\u003c\/strong\u003e. The official opening in India is noted as \u003cstrong\u003eNovember 1st, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The strategy is clearly articulated and supported by operational learnings from Latin America. The company is on track with its plans for \u003cstrong\u003eQ4\u003c\/strong\u003e market pre-opening activities in India.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary.\u003c\/p\u003e\n\u003cp\u003eThe strategic focus on developing markets is quantified by the following comparative data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatin America (Q2 2025 Performance)\u003c\/th\u003e\n\u003cth\u003eIndia (Expansion Plan)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e107%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Pre-launch)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Entry Activity\u003c\/td\u003e\n\u003ctd\u003eEstablished\/Simplified Model\u003c\/td\u003e\n\u003ctd\u003ePre-opening activities in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormal Launch Timeline\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eMid-\u003cstrong\u003e2026\u003c\/strong\u003e (or \u003cstrong\u003eNovember 1, 2025\u003c\/strong\u003e official opening)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Potential (Direct Sales)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eProjected \u003cstrong\u003e$100 Billion\u003c\/strong\u003e by \u003cstrong\u003e2030\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy Focus\u003c\/td\u003e\n\u003ctd\u003eLocalized Product Portfolios, Digital-First\u003c\/td\u003e\n\u003ctd\u003eLocalized Product Portfolios, Digital-First, Local Manufacturing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational metrics supporting the turnaround, which underpins the expansion funding:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ2 2025 Operating Margin: \u003cstrong\u003e8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating Margin Improvement YoY: \u003cstrong\u003e260-basis-point\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Customers (Q2 2025): \u003cstrong\u003e771,407\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Sales Leaders (Q2 2025): \u003cstrong\u003e29,593\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe India strategy includes leveraging success principles from Latin America and focusing on a localized product portfolio and digital-first infrastructure. The company also plans to introduce Ayurveda-inspired global-quality wellness products and expand professional salon-grade offerings in India.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Operational Efficiency \u0026amp; Cost Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Drives profitability despite top-line pressure, resulting in an operating margin of \u003cstrong\u003e8.0%\u003c\/strong\u003e in Q2 2025, up from an adjusted operating margin of \u003cstrong\u003e5.4%\u003c\/strong\u003e the prior year (excluding impairment and other charges).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies cut costs, but achieving five consecutive quarters of improving adjusted gross margin in the core Nu Skin business is notable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Cost structures are company-specific, but the results, such as the \u003cstrong\u003e8.0%\u003c\/strong\u003e operating margin, are achievable by disciplined peers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The success of cost-cutting initiatives is a consistent theme in 2025 reporting, evidenced by specific expense reductions and balance sheet improvements.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary.\u003c\/p\u003e\n\u003cp\u003eThe operational discipline is further detailed by the following financial metrics comparing Q2 2025 to Q2 2024:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Value\u003c\/td\u003e\n\u003ctd\u003eQ2 2024 Value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e68.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNu Skin Business Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e76.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling Expenses (% of Revenue)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e37.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses (% of Revenue)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey organizational achievements supporting this efficiency include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses were down \u003cstrong\u003e$11.2 million\u003c\/strong\u003e compared to Q2 of 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company generated \u003cstrong\u003e$35.8 million\u003c\/strong\u003e in Cash Flow from Operations in Q2 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company reached a positive net cash position ahead of schedule for the first time in more than \u003cstrong\u003e4 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe core Nu Skin business gross margin improvement to \u003cstrong\u003e77.5%\u003c\/strong\u003e marked the \u003cstrong\u003efourth consecutive quarter\u003c\/strong\u003e of year-over-year improvement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNu Skin Enterprises, Inc. (NUS) - VRIO Analysis: Product Portfolio Rationalization\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSimplifies operations, reduces inventory complexity, and focuses resources on high-potential products. Plan to cut the portfolio by over 50% by the end of 2025. Progress noted with a target of a \u003cstrong\u003e20%\u003c\/strong\u003e reduction by end of \u003cstrong\u003e2024\u003c\/strong\u003e to improve gross margin. Q2 2024 revenue was \u003cstrong\u003e$439.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Aggressive portfolio pruning is a bold move that not all companies execute well.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. This is an internal, strategic decision based on their specific SKU count and operational needs.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. The plan is concrete, with a clear deadline for completion.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.73 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRhyz Revenue\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$286.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Customers\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (September 30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e746,256\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Paid Affiliates\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (September 30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e130,096\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Sales Leaders\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (September 30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31,150\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$111.74 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.16 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey operational and financial metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$364.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2025 Full-Year Revenue Forecast: \u003cstrong\u003e$1.48 billion\u003c\/strong\u003e to \u003cstrong\u003e$1.51 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStrategic transaction of Mavely for \u003cstrong\u003e$250 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eStock Repurchases (Q3 2025): \u003cstrong\u003e$5.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRemaining Stock Repurchase Authorization: \u003cstrong\u003e$152.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eFinance\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eOperating cash flow for 2024 was \u003cstrong\u003e$111.74 million\u003c\/strong\u003e. Free cash flow for 2024 was \u003cstrong\u003e$70.16 million\u003c\/strong\u003e. Q3 2025 Interest Expense was \u003cstrong\u003e$4.1 million\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516219547797,"sku":"nus-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/nus-vrio-analysis.png?v=1740200629","url":"https:\/\/dcf-model.com\/pt\/products\/nus-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}